A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins
Joohi Jimenez-ShahedDepartment of Neurology, Baylor College of Medicine, Houston, TX, USAAbstract: Dystonia is a movement disorder of uncertain pathogenesis that is characterized by involuntary and inappropriate muscle contractions which cause sustained abnormal postures and movements of multiple or...
Guardado en:
Autor principal: | Jimenez-Shahed J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/798f4f67d7994e27a77c07077ecddca3 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm
por: Park J, et al.
Publicado: (2011) -
Safety and efficacy of incobotulinumtoxinA as a potential treatment for poststroke spasticity
por: Santamato A
Publicado: (2016) -
Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines
por: Prager W
Publicado: (2013) -
Onset, longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study
por: Prager W, et al.
Publicado: (2013) -
Neurologic uses of botulinum neurotoxin type A
por: John P Ney, et al.
Publicado: (2007)